drugset

drugset / Trial / NCT07399678

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

NCT07399678 ↗

Phase 1 Recruiting 180 enrolled Alveus Therapeutics, Inc.

RandomizedSequentialQuadruple-blindTreatment

Summary

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Timeline

Start: 2025-12-29
Primary completion: 2027-04
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALV-100	Unknown	—	Subcutaneous

Indications